| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Biology, Pathobiology, and Genetics |
1 Center for Advanced Biotechnology and Medicine, 2 The Cancer Institute of New Jersey, and Departments of 3 Medicine and 4 Pediatrics, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, Piscataway, New Jersey
Requests for reprints: Cory Abate-Shen, Center for Advanced Biotechnology and Medicine, 679 Hoes Lane, Piscataway, NJ 08854. Phone: 732-235-5161; Fax: 732-235-5789; E-mail: abate{at}cabm.rutgers.edu and Michael M. Shen. Phone: 732-235-5645; Fax: 732-235-5373; E-mail: mshen{at}cabm.rutgers.edu.
Although androgen deprivation therapy is a widely used treatment for patients with advanced prostate cancer, it ultimately results in the emergence of a hormone-refractory disease that is invariably fatal. To provide insights into the genesis of this disease, we have employed an in vivo model to investigate how and when prostate epithelial cells can acquire the ability to survive and proliferate in the absence of androgens. In particular, we have been studying the evolution of androgen independence in Nkx3.1; Pten mutant mice, which develop prostatic intraepithelial neoplasia and adenocarcinoma as a consequence of aging, as well as androgen-independent phenotypes following castration. We now find that the prostate epithelial cells from these Nkx3.1; Pten mutant mice are capable of surviving and proliferating in the absence of androgens and that they develop androgen-independent phenotypes well before they display overt prostatic intraepithelial neoplasia or cancer phenotypes. Our findings in this mouse model show that acquisition of androgen independence can be uncoupled from overt cancer progression and raise the possibility that hormone-refractory disease can arise at early stages of prostate carcinogenesis. (Cancer Res 2006; 66(16): 7929-33)
This article has been cited by other articles:
![]() |
W. Banach-Petrosky, W. J. Jessen, X. Ouyang, H. Gao, J. Rao, J. Quinn, B. J. Aronow, and C. Abate-Shen Prolonged Exposure to Reduced Levels of Androgen Accelerates Prostate Cancer Progression in Nkx3.1; Pten Mutant Mice Cancer Res., October 1, 2007; 67(19): 9089 - 9096. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. M. Shen and C. Abate-Shen Pten Inactivation and the Emergence of Androgen-Independent Prostate Cancer Cancer Res., July 15, 2007; 67(14): 6535 - 6538. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Jiao, S. Wang, R. Qiao, I. Vivanco, P. A. Watson, C. L. Sawyers, and H. Wu Murine Cell Lines Derived from Pten Null Prostate Cancer Show the Critical Role of PTEN in Hormone Refractory Prostate Cancer Development Cancer Res., July 1, 2007; 67(13): 6083 - 6091. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |